Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

OBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type i...

Full description

Bibliographic Details
Main Authors: Sophie Kirshberg, Uzi Izhar, Gail Amir, Jonathan Demma, Fiona Vernea, Katia Beider, Zippora Shlomai, Hanna Wald, Gideon Zamir, Oz M Shapira, Amnon Peled, Ori Wald
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3174223?pdf=render
id doaj-92051df2fab7467db6dcba7266ebef30
record_format Article
spelling doaj-92051df2fab7467db6dcba7266ebef302020-11-25T01:42:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0169e2485610.1371/journal.pone.0024856Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.Sophie KirshbergUzi IzharGail AmirJonathan DemmaFiona VerneaKatia BeiderZippora ShlomaiHanna WaldGideon ZamirOz M ShapiraAmnon PeledOri WaldOBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type immune response in NSCLC is not yet defined. We sought to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth. METHODS: A specialized histopathologist blindly assessed CCL20/CCR6 expression levels in 49 tissue samples of NSCLC patients operated in our department. Results were correlated to disease progression. Colony assays, ERK signaling and chemokine production were measured to assess cancer cell responsiveness to CCL20 and IL-17 stimulation. RESULTS: CCL20 was highly expressed in the majority (38/49, 77.5%) of tumor samples. Only a minority of samples (8/49, 16.5%) showed high CCR6 expression. High CCR6 expression was associated with a shorter disease-free survival (P = 0.008) and conferred a disease stage-independent 4.87-fold increased risk for disease recurrence (P = 0.0076, CI 95% 1.52-15.563). Cancerous cell colony-forming capacity was increased by CCL20 stimulation; this effect was dependent in part on ERK phosphorylation and signaling. IL-17 expression was detected in NSCLC; IL-17 potentiated the production of CCL20 by cancerous cells. CONCLUSION: Our findings suggest that the CCL20/CCR6 axis promotes NSCLC disease progression. CCR6 is identified as a potential new prognostic marker and the CCL20/CCR6/IL-17 axis as a potential new therapeutic target. Larger scale studies are required to consolidate these observations.http://europepmc.org/articles/PMC3174223?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sophie Kirshberg
Uzi Izhar
Gail Amir
Jonathan Demma
Fiona Vernea
Katia Beider
Zippora Shlomai
Hanna Wald
Gideon Zamir
Oz M Shapira
Amnon Peled
Ori Wald
spellingShingle Sophie Kirshberg
Uzi Izhar
Gail Amir
Jonathan Demma
Fiona Vernea
Katia Beider
Zippora Shlomai
Hanna Wald
Gideon Zamir
Oz M Shapira
Amnon Peled
Ori Wald
Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
PLoS ONE
author_facet Sophie Kirshberg
Uzi Izhar
Gail Amir
Jonathan Demma
Fiona Vernea
Katia Beider
Zippora Shlomai
Hanna Wald
Gideon Zamir
Oz M Shapira
Amnon Peled
Ori Wald
author_sort Sophie Kirshberg
title Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
title_short Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
title_full Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
title_fullStr Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
title_full_unstemmed Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.
title_sort involvement of ccr6/ccl20/il-17 axis in nsclc disease progression.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description OBJECTIVES: Autocrine and paracrine chemokine/chemokine receptor-based interactions promote non-small-cell-lung-cancer (NSCLC) carcinogenesis. CCL20/CCR6 interactions are involved in prostatic and colonic malignancy pathogenesis. The expression and function of CCL20/CCR6 and its related Th-17 type immune response in NSCLC is not yet defined. We sought to characterize the role of the CCL20/CCR6/IL-17 axis in NSCLC tumor growth. METHODS: A specialized histopathologist blindly assessed CCL20/CCR6 expression levels in 49 tissue samples of NSCLC patients operated in our department. Results were correlated to disease progression. Colony assays, ERK signaling and chemokine production were measured to assess cancer cell responsiveness to CCL20 and IL-17 stimulation. RESULTS: CCL20 was highly expressed in the majority (38/49, 77.5%) of tumor samples. Only a minority of samples (8/49, 16.5%) showed high CCR6 expression. High CCR6 expression was associated with a shorter disease-free survival (P = 0.008) and conferred a disease stage-independent 4.87-fold increased risk for disease recurrence (P = 0.0076, CI 95% 1.52-15.563). Cancerous cell colony-forming capacity was increased by CCL20 stimulation; this effect was dependent in part on ERK phosphorylation and signaling. IL-17 expression was detected in NSCLC; IL-17 potentiated the production of CCL20 by cancerous cells. CONCLUSION: Our findings suggest that the CCL20/CCR6 axis promotes NSCLC disease progression. CCR6 is identified as a potential new prognostic marker and the CCL20/CCR6/IL-17 axis as a potential new therapeutic target. Larger scale studies are required to consolidate these observations.
url http://europepmc.org/articles/PMC3174223?pdf=render
work_keys_str_mv AT sophiekirshberg involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT uziizhar involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT gailamir involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT jonathandemma involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT fionavernea involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT katiabeider involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT zipporashlomai involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT hannawald involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT gideonzamir involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT ozmshapira involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT amnonpeled involvementofccr6ccl20il17axisinnsclcdiseaseprogression
AT oriwald involvementofccr6ccl20il17axisinnsclcdiseaseprogression
_version_ 1725035959836213248